Forest Laboratories receives patent term extension for Lexapro

By Lisa Kerner

Erie, Pa., March 2 - Forest Laboratories, Inc. said it received an 828-day extension from the U.S. Patent and Trademark Office for its U.S. Patent No. Re. 34,712.

The patent covers the composition of matter for Lexapro (escitalopram oxalate) for the treatment of major depressive disorder and generalized anxiety disorder in adults, according to a company news release.

The patent will now expire on Sept. 14, 2011. An additional six-month exclusivity period provided by the pediatric indication for the drug pushes the patent term to March 14, 2012, the company said.

Forest Laboratories is a New York-based pharmaceutical company that develops therapeutics to treat disorders of the central nervous, respiratory and cardiovascular systems.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.